FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1

Wake Up and Do Something: Califf on Misinformation

FDA commissioner Robert Califf tells a George Washington University presentation on healthcare misinformation and disinformation that the country need...

latest-news-card-1
Human Drugs

Chinese API Maker Hit with FDA-483

FDA posts a six-item Form FDA-483 from a 9/2023 inspection at Sichuan Deebio Pharmaceutical Co. in Guanghan, Sichuan, China.

latest-news-card-1
Medical Devices

De Novo Pathway Challenges and Opportunities

Three academic researchers say the FDA de novo medical device pathway has the potential to attract innovators who want to define new categories of dev...

latest-news-card-1

CDER Tests Communications for Clarity

CDER Office of Communications social scientist Alexandria Smith says the Center tests some communications intended for consumers or healthcare profess...

latest-news-card-1
Federal Register

Comments Sought on Drug Scheduling Recommendations

Federal Register notice: FDA seeks comments concerning recommendations by the World Health Organization to impose international manufacturing and dist...

latest-news-card-1
Medical Devices

Philips BrightView CT System Recalled

Philips North America recalls its BrightView computed tomography gamma camera system because of the risk of the detector unexpectedly falling.

Human Drugs

FDA Accepts Opdivo sNDA for New Indication

FDA sets a 10/8 PDUFA action date for a Bristol Myers Squibb sNDA for Opdivo to treat some non-small cell lung cancers.

latest-news-card-1
Human Drugs

Amneal Refiles NDA for Parkinsons Drug

Amneal Pharmaceuticals resubmits an NDA for IPX203, a novel oral formulation of carbidopa/levodopa extended-release capsules for treating Parkinsons d...

latest-news-card-1
Federal Register

Panel to Select Flu Vaccine Strain Target

Federal Register notice: FDA announces a 3/5 meeting of the advisory committee that will discuss strains to be included in next seasons flu vaccine.

latest-news-card-1
Biologics

Amgen Seeks Expanded Blincyto Indication

FDA accepts for priority review an Amgen supplemental BLA for Blincyto (blinatumomab) for treating early-stage, CD19-positive B-cell precursor acute l...